Evolving Risk Factors for Mortality, Progression, Myeloid Dysplasia and Survival in Large 2-Decade Single-Centre Autologous Transplant Cohort of Myeloma, Amyloidosis and related Plasma Cell Dyscrasia

Abstract

Autologous Stem Cell Transplant (ASCT) with High-Dose Melphalan conditioning has been a unchallenged standard for intensive consolidation therapy in younger fitter Multiple Myeloma (MM) since late 1990, & was ratified as increasing PFS & OS, through RCT by various collaborative groups, as well as meta-analysis.However induction regimens have evolved from anthracycline-based infusions (e.g. [C]VAD & DTPACE]), through thal- & now len- alidomide-based IMid regimens (CTD/DTPACE/CRD), alongside advent of proteasome-inhibitors (esp.